Can-Fite develops small molecule therapeutic products for the treatment of autoimmune-inflammatory and cancer.
Business Model:
Revenue: $755k
Employees: 2-10
Address: 10 Bareket Street
City: Petah Tikva
State: center district
Zip: 49170
Country: IL
Can-Fite develops small molecule therapeutic products for the treatment of autoimmune-inflammatory and cancer.
Contact Phone:
Contact Email:
Listed Exchange:
NYSE
IPO Date:
4/3/2014
Ticker Symbol:
CANF
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2002 | Venture Round | 4 | $12M |
Yozma Group SCP Vitalife Partners Giza Venture Capital Ascend Technology Ventures Yozma Group SCP Vitalife Partners Giza Venture Capital Ascend Technology Ventures |
4/2019 | Equity | $1M |
Chong Kun Dang Pharmaceuticals |
1/2017 | Post-IPO Equity | $5M | 3/2018 | Equity | $6.6M | 10/2015 | Post-IPO Debt | $9M | 9/2019 | Post-IPO Equity | 1 | $2.4M |
Cybele Holdings Cybele Holdings |
8/2021 | Post-IPO Equity | $10M | 10/2015 | Unattributed | $4.8M | 9/2015 | Equity | $9M | 12/2014 | Post-IPO Equity | $8M | 2/2013 | Post-IPO Equity | $7.2M | 7/2020 | Post-IPO Equity | $11.4M | 1/2023 | Post-IPO Equity | $7.5M | 9/2015 | Post-IPO Equity | $9M | 4/2013 | Post-IPO Equity | 1 | $1.4M |
Cybele Holdings Cybele Holdings |
3/2014 | Post-IPO Equity | $5M | 9/2019 | Post-IPO Equity | 1 | $2.4M |
Cybele Holdings Cybele Holdings |
4/2013 | Post-IPO Equity | 1 | $1.4M |
Cybele Holdings Cybele Holdings |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|